Key result
Fuzheng Yangxin Granule will be evaluated for its efficacy and safety in improving peak oxygen uptake among 150 patients with heart failure with preserved ejection fraction in a planned randomized controlled trial.
Why the study?
Few clinical trials use rigorous methodologies to evaluate the efficacy and safety of traditional Chinese medicine for heart failure with preserved ejection fraction.
Does Fuzheng Yangxin Granule improve maximal peak oxygen uptake in patients with HFpEF and Qi-Yin deficiency and blood stasis syndrome?
Population
150 participants aged 18–80 years with confirmed HFpEF (Qi-Yin deficiency and blood stasis syndrome) across seven Chinese tertiary hospitals
Comparison
Fuzheng Yangxin Granule vs placebo, alongside standardized Western medical therapy
Design
Multicenter, double-blind randomized controlled trial protocol
Follow-up
12-week intervention plus 40-week safety follow-up
Authors
Loading...
Does not yet support Fuzheng Yangxin Granule in HFpEF; RCT will clarify efficacy on peak VO2.
RCT (n=150)
Double-blind
Blocked randomization
Yes
Does Fuzheng Yangxin Granule improve maximal peak oxygen uptake in patients with HFpEF and Qi-Yin deficiency and blood stasis syndrome?
This study protocol describes a planned multicenter RCT to evaluate whether Fuzheng Yangxin Granule improves peak oxygen uptake in patients with HFpEF.
Chen et al. (2025) conducted an RCT in Heart failure with preserved ejection fraction (HFpEF) (n=150). Fuzheng Yangxin Granule vs. Placebo was evaluated on Maximal peak oxygen uptake (peak VO2). Fuzheng Yangxin Granule will be evaluated for its efficacy and safety in improving peak oxygen uptake among 150 patients with heart failure with preserved ejection fraction in a planned randomized controlled trial.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: